Skip to Content

Label Changes for:

Anzemet (dolasetron mesylate)

September 2013

Changes have been made to the PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


September 2013

changes: remove all information for the prevention of postoperative nausea and vomiting based on current guidelines regarding the administration of oral Anzemet prior to surgery in the following sections:


Drug Interactions
Geriatric Use